Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Simple Blood Tests for Signaling Proteins Could Predict Cancer or Inflammation

By LabMedica International staff writers
Posted on 24 Feb 2023

Telomeres, sections of DNA found at the ends of our chromosomes, were first identified by scientists around 80 years ago. More...

Telomeres contain a unique DNA sequence consisting of endless repeats of TTAGGG bases that prevent chromosomes from sticking to each other. Telomeres were once believed to be incapable of encoding proteins due to their simple monotonous repetitions of DNA. Two decades ago, researchers demonstrated that the end of a telomere’s DNA loops back on itself to form a tiny circle, thereby hiding the end and blocking chromosome-to-chromosome fusions. When cells divide, telomeres shorten, eventually becoming so short that the cell is unable to divide properly anymore, leading to cell death. Now, the same researchers have found that telomeres hold a potent biological function that could be relevant to our understanding of cancer and aging.

Researchers at UNC School of Medicine (Chapel Hill, NC, USA) have made the stunning discovery that telomeres hold genetic information to produce two small proteins, one of which was found to be elevated in specific human cancer cells and cells from patients with telomere-related defects. In 2011, a group of researchers studying an inherited form of ALS found that an RNA molecule containing a six-base repeat could by a novel mechanism generate a series of toxic proteins consisting of two amino acids repeating one after the other. In the latest study, the researchers found a striking similarity of this RNA to the RNA generated from human telomeres, and believe that the same novel mechanism could be in play.

They conducted experiments to show how telomeric DNA can instruct the cell to produce signaling proteins termed as VR (valine-arginine) and GL (glycine-leucine). Signaling proteins are basically chemicals that trigger a chain reaction of other proteins inside cells that eventually lead to a biological function important for health or disease. The researchers then chemically synthesized VR and GL to examine their properties using powerful electron and confocal microscopes, accompanied by state-of-the-art biological methods. They found elevated amounts of VR protein in some human cancer cells and in cells from patients suffering from diseases as a result of defective telomeres.

“Based on our research, we think simple blood tests for these proteins could provide a valuable screen for certain cancers and other human diseases,” said Jack Griffith, the Kenan Distinguished Professor of Microbiology and Immunology and member of the UNC Lineberger Comprehensive Cancer Center. “These tests also could provide a measure of ‘telomere health,’ because we know telomeres shorten with age.”

“Many questions remain to be answered, but our biggest priority now is developing a simple blood test for these proteins. This could inform us of our biological age and also provide warnings of issues, such as cancer or inflammation,” added Griffith.

Related Links:
UNC School of Medicine 


Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated PCR Setup
ESTREAM
New
Modular Hemostasis Automation Solution
CN Track
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: Micrograph showing the distribution of misfolded proteins in myeloma cells (Photo courtesy of Helmholtz Munich)

Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. Traditional methods for evaluating myeloma... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.